Prostate Cancer Reports


Volume 1 Number 1
 January 2013

Home > Prostate Cancer Reports > Volume 1 - Year 2013 > Number 1, January 2013

CONTENTS


Prostate cancer
Recurrent prostate cancer
Advanced prostate cancer


PROSTATE CANCER


Overview

Albertsen PC.
What is the risk posed by prostate cancer?
J Natl Cancer Inst Monogr. 2012 Dec;2012(45):169-74. doi: 10.1093/jncimonographs/lgs028.
Article | PubMed | Reprint | Related citations

 

Erectile dysfunction

Basal S, Wambi C, Acikel C, Gupta M, Badani K.
Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function.
BJU Int. 2013 Apr;111(4):658-65. doi: 10.1111/j.1464-410X.2012.11487.x. Epub 2012 Nov 27.
Abstract | Related citations

 

Carter S, Le JD, Hu JC.
Anatomic and technical considerations for optimizing recovery of sexual function during robotic-assisted radical prostatectomy.
Curr Opin Urol. 2013 Jan;23(1):88-94. doi: 10.1097/MOU.0b013e32835b6602.
Abstract | Related citations

 

Røder MA, Thomsen FB, Christensen IJ, Toft BG, Brasso K, Vainer B, Iversen P.
Risk factors associated with positive surgical margins following radical prostatectomy for clinically localized prostate cancer: Can nerve-sparing surgery increase the risk?
Scand J Urol. 2012 Nov 27. [Epub ahead of print]
Abstract | Related citations

 

Gleason score 6

Heidegger I, Ladurner M, Skradski V, Klocker H, Schäfer G, Horninger W, Bektic J.
Adverse pathological findings in needle biopsy gleason score 6 prostate cancers with low and intermediate preoperative PSA levels following radical prostatectomy.
Anticancer Res. 2012 Dec;32(12):5481-5.
Abstract |
Related citations


Integrative medicine

Chua ME, Sio MC, Sorongon MC, Dy JS.
Relationship of dietary intake of omega-3 and omega-6 Fatty acids with risk of prostate cancer development: a meta-analysis of prospective studies and review of literature.
Prostate Cancer. 2012;2012:826254. doi: 10.1155/2012/826254. Epub 2012 Oct 18.
Abstract | Full text | Related citations

 

Neoadjuvant hormonal therapy

Naiki T, Kawai N, Okamura T, Nagata D, Kojima Y, Akita H, Yasui T, Tozawa K, Kohri K.
Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy.
BMC Urol. 2012 Dec 18;12:36. doi: 10.1186/1471-2490-12-36.
Abstract | Full text |
Related citations


Radiation complications

Okajima K, Ishikawa K, Matsuura T, Tatebe H, Fujiwara K, Hiroi K, Hasegawa H, Nishimura Y.
Multiple primary malignancies in patients with prostate cancer: increased risk of secondary malignancies after radiotherapy.
Int J Clin Oncol. 2012 Nov 20. [Epub ahead of print]
Abstract | Related citations

 
RECURRENT PROSTATE CANCER


Bruce JY, Lang JM, McNeel DG, Liu G.
Current controversies in the management of biochemical failure in prostate cancer.
Clin Adv Hematol Oncol. 2012 Nov;10(11):716-22.
Abstract | Full text |
Related citations


Detti B, Scoccianti S, Franceschini D, Cipressi S, Cassani S, Villari D, Gacci M, Pupi A, Vaggelli L, Saieva C, Pertici M, Livi L, Ceroti M, Nicita G, Carini M, Biti G.
Predictive factors of [18F]-Choline PET/CT in 170 patients with increasing PSA after primary radical treatment.
J Cancer Res Clin Oncol. 2013 Mar;139(3):521-8. doi: 10.1007/s00432-012-1354-4. Epub 2012 Nov 27.
Abstract |
Related citations


Kato K, Inoue T, Mizowaki T, Kamoto T, Kamba T, Shimizu Y, Norihisa Y, Yamada T, Hiraoka M, Yoshimura K, Ogawa O.
[Salvage hormonal therapy against recurrence after curative external beam radiotherapy for locally advanced prostate cancer at Kyoto University Hospital].
Hinyokika Kiyo. 2012 Nov;58(11):599-603. Japanese.
Abstract |
Related citations


Nguyen DP, Giannarini G, Seiler R, Schiller R, Thoeny HC, Thalmann GN, Studer UE.
Local recurrence after retropubic radical prostatectomy for prostate cancer does not exclusively occur at the anastomotic site.
BJU Int. 2012 Nov 27. doi: 10.1111/j.1464-410X.2012.11506.x. [Epub ahead of print]
Abstract |
Related citations


Schröder F, Bangma C, Angulo JC, Alcaraz A, Colombel M, McNicholas T, Tammela TL, Nandy I, Castro R.
Dutasteride Treatment Over 2 Years Delays Prostate-specific Antigen Progression in Patients with Biochemical Failure After Radical Therapy for Prostate Cancer: Results from the Randomised, Placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS).
Eur Urol. 2013 May;63(5):779-87. doi: 10.1016/j.eururo.2012.11.006. Epub 2012 Nov 12.
Abstract |
Related citations


Uchio EM, Aslan M, Wells CK, Calderone J, Concato J.
Impact of biochemical recurrence in prostate cancer among US veterans.
Arch Intern Med. 2010 Aug 9;170(15):1390-5. doi: 10.1001/archinternmed.2010.262.
Abstract | Full text |
Related citations


Steigler A, Denham JW, Lamb DS, Spry NA, Joseph D, Matthews J, Atkinson C, Turner S, North J, Christie D, Tai KH, Wynne C.
Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial.
Prostate Cancer. 2012;2012:814724. doi: 10.1155/2012/814724. Epub 2012 Dec 24.
Abstract | Full text |
Related citations

ADVANCED PROSTATE CANCER


Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M.
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
J Clin Oncol. 2013 Feb 1;31(4):412-9. doi: 10.1200/JCO.2012.45.0494. Epub 2012 Nov 19.
Abstract | Full text |
Related citations